What does CUSIP 92765F108 represent in this 13F holders report?

CUSIP 92765F108 is the security identifier for VIRX - Viracta Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held VIRX - Viracta Therapeutics, Inc. - Common Stock in Q2 2022?

51 institutional investors reported VIRX - Viracta Therapeutics, Inc. - Common Stock for Q2 2022. Use the holders table for investor-level position and value details.

Viracta Therapeutics, Inc. - Common Stock (VIRX)

CUSIP: 92765F108

Q2 2022 13F Holders as of 30 Jun 2022

Security type / class: Equity / Common Stock
Total 13F shares: 11,367,208
Total 13F value: $44,104,000
Share change: -1,451,836
Put/Call ratio: 32%
SEC-reported price per share: $3.88
Number of holders: 51
Value change: -$5,935,339
Number of buys: 19
Number of sells: 37
Shares outstanding: 19,711,628

Security key

92765F108

Report period

Q2 2022

Institutions

Top holders

VIRX full security history Ownership snapshot Full 13F holder table Viracta Therapeutics, Inc. SEC filings Viracta Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VIRX - Viracta Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

BVF INC/IL

Disclosed value leader

BVF INC/IL

Comparable rows

15/15

Latest evidence

31 Mar 2022

13F Lead comparable stake: 18% Showing 1-6 of 15 holder rows.

Quick read

BVF INC/IL leads the comparable SEC ownership view at 18%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BVF INC/IL's linked filing trail.

Comparable ownership Top 5

BVF INC/IL 18%

BlackRock Finance, Inc. 12%

CITADEL ADVISORS LLC 7.9%

VANGUARD GROUP INC 4.2%

Samsara BioCapital, LLC 3.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
BVF INC/IL	13F Company 13F	18%	$17,206,000 3,614,662 shares	—	31 Mar 2022
BlackRock Finance, Inc.	13F Company 13F	12%	$11,010,000 2,312,908 shares	—	31 Mar 2022
CITADEL ADVISORS LLC	13F Company 13F	7.9%	$7,450,000 1,565,014 shares	—	31 Mar 2022
VANGUARD GROUP INC	13F Company 13F	4.2%	$3,945,000 828,877 shares	—	31 Mar 2022
Samsara BioCapital, LLC	13F Company 13F	3.6%	$3,385,000 711,039 shares	—	31 Mar 2022
STATE STREET CORP	13F Company 13F	3%	$2,802,000 588,603 shares	—	31 Mar 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

11,367,208

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Q2 2022 holders

Holder diff

-10

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 value	Q2 2022 value	Value change	Value Chg %